You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer

  • Technology appraisal guidance
  • Reference number: TA212
  • Published:  15 December 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Colorectal cancer (metastatic) - bevacizumab: consultee and commentator comments on the ACD

  • Colorectal cancer (metastatic) - bevacizumab: Roche

  • Colorectal cancer (metastatic) - bevacizumab: Bowel Cancer UK

  • Colorectal cancer (metastatic) - bevacizumab: Royal College of Nursing

  • Colorectal cancer (metastatic) - bevacizumab: National Collaborating Centre for Cancer


This page was last updated: 09 November 2010

Back to top